Our Company | Learn About Freenome's Team

Cutting-edge innovation driven by our purpose

Since 2014, Freenome has had a clear vision—to detect cancer in its earliest, most treatable stages.

Close

Board of Directors

We are values-led

At Freenome, our values guide everything we do.

STRIVE FOR GREATNESS

We choose to take on cancer not because it’s easy, but because it’s hard.

SERVANT LEADERSHIP

We lead by example and help others grow to their full potential.

TRUST

We recognize trust is built over time and value long-term relationships, not short-term transactions.

INTEGRITY

We courageously do what is right, and are fact-based, data-driven, and accountable for results.

EMPATHY

We seek to understand before being understood and build products that equitably serve diverse communities.

Leadership

Board of Directors

Aaron Elliott, Ph.D.
Chief Executive Officer, Freenome

Ellen Hukkelhoven, Ph.D.
Head of Biotechnology Investments, Perceptive Advisors

Carole Nuechterlein
Former Head, Roche Venture Fund

Randy Scott, Ph.D.
Chief Executive Officer, Thinking Bench Capital, LLC

Ann Costello
Former Head, Roche Diagnostics Solutions

Peter Kolchinsky, Ph.D.
Managing Partner, RA Capital Management LP

Deepa Pakianathan, Ph.D.
Chief Executive Officer, a stealth Biotech Company

Douglas VanOort
Former Chairman and Chief Executive Officer, NeoGenomics Inc.

Aaron Elliott, Ph.D.
Chief Executive Officer, Freenome

Ann Costello
Former Head, Roche Diagnostics Solutions

Ellen Hukkelhoven, Ph.D.
Head of Biotechnology Investments, Perceptive Advisors

Peter Kolchinsky, Ph.D.
Managing Partner, RA Capital Management LP

Carole Nuechterlein
Former Head, Roche Venture Fund”

Deepa Pakianathan, Ph.D.
Chief Executive Officer, a stealth Biotech Company

Randy Scott, Ph.D.
Chief Executive Officer, Thinking Bench Capital, LLC

Douglas VanOort
Former Chairman and Chief Executive Officer, NeoGenomics Inc.

Investors

* Funds and accounts advised by T. Rowe Price Associates, Inc.